🇺🇸 FDA
Patent

US 7601709

Macrocyclic hepatitis C serine protease inhibitors

granted A61KA61K38/12A61P

Quick answer

US patent 7601709 (Macrocyclic hepatitis C serine protease inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Oct 08 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue Oct 13 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 08 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
75
CPC classes
A61K, A61K38/12, A61P, A61P31/12